Abstract | PURPOSE: The anti- tumor properties of thalidomide or in combination with an oncolytic herpes virus (OncdSyn) was investigated in a mouse model of human breast cancer. METHODS: RESULTS:
Thalidomide alone suppressed tumor growth. The most significant treatment occurred in thalidomide-fed-OncdSyn-injected mice. Compared to PBS controls, there was a significant difference in the number of metastatic nodes in the lungs. CONCLUSIONS:
|
Authors | Anna Israyelyan, Edward John Shannon, Abolghasem Baghian, Michael T Kearney, Konstantin G Kousoulas |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 64
Issue 6
Pg. 1201-10
(Nov 2009)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 19308409
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Interleukin-2
- Interleukin-5
- Thalidomide
- Granulocyte-Macrophage Colony-Stimulating Factor
|
Topics |
- Animals
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Coculture Techniques
- Combined Modality Therapy
(methods)
- Female
- Granulocyte-Macrophage Colony-Stimulating Factor
(metabolism)
- Herpesvirus 1, Human
(genetics, physiology)
- Humans
- Interleukin-2
(metabolism)
- Interleukin-5
(metabolism)
- Lung Neoplasms
(drug therapy, pathology, secondary, therapy)
- Lymphocytes
(drug effects, metabolism)
- Mammary Neoplasms, Experimental
(drug therapy, pathology, therapy)
- Mice
- Mice, Inbred BALB C
- Oncolytic Virotherapy
(methods)
- Spleen
(cytology, drug effects)
- Thalidomide
(administration & dosage, pharmacology, therapeutic use)
- Treatment Outcome
|